Turkish competition authorities launched an investigation into Teva Pharmaceutical Industries for alleged anti-competitive practices. The probe focuses on whether the company violated local laws to hinder market competitors.
Investigators are examining the strategic use of patents and the provision of misleading information to health officials. These actions allegedly restricted the availability of generic drugs.
The investigation targets Teva International, its European division, and its Turkish subsidiary.
Teva previously faced similar antitrust charges from the European Commission regarding its drug Copaxone.